Application of D-cycloserine in preparation of medicine for preventing / treating inflammatory bowel disease

By reducing inflammatory factors and upregulating tight junction proteins, D-cycloserine solves the side effects and insufficient efficacy of inflammatory bowel disease treatment in the prior art, and achieves effective prevention and treatment of inflammatory bowel disease without liver and kidney toxicity.

CN119033776APending Publication Date: 2024-11-29SOUTH CHINA AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411006780.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing inflammatory bowel disease treatment drugs have side effects and cannot be used for a long time, and cannot completely control the disease. The relationship between the imbalance of tight junction proteins and intestinal inflammation is unclear, making it difficult for the treatment to effectively restore the integrity of the epithelial barrier.

Method used

D-cycloserine is used to prevent and treat inflammatory bowel disease by reducing the levels of inflammatory factors IL-1β and/or IL-18 and/or IL-6, reducing intestinal barrier permeability and upregulating tight juncin expression. .

Benefits of technology

D-cycloserine effectively reduces the level of inflammatory factors, restores intestinal barrier integrity, significantly alleviates the symptoms of inflammatory bowel disease, and has no liver and nephrotoxicity, providing a feasible drug regimen for preventing and treating inflammatory bowel disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033776A_ABST
    Figure CN119033776A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of new application of medicines, and discloses application of D-cycloserine in preparation of medicines for preventing / treating inflammatory bowel diseases. The development of the compound D-cycloserine for preventing / treating the mouse inflammatory bowel disease is evaluated, and the compound is found to be capable of reducing the intestinal inflammatory response and up-regulating tight junction protein to protect the intestinal barrier, so that the symptoms of the mouse inflammatory bowel disease induced by DSS are effectively prevented and / or treated, and the development of the compound D-cycloserine for preventing / treating the mouse inflammatory bowel disease is promoted. Meanwhile, the detection of liver and kidney indexes shows that the D-cycloserine has no obvious liver and kidney toxicity, so that the D-cycloserine can be used for preparing the medicine for preventing and / or treating the inflammatory bowel disease, and a feasible scheme can be provided for preventing the inflammatory bowel disease in clinical medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of new drug applications, and more specifically, relates to the application of D-cycloserine in the preparation of drugs for preventing / treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a group of chronic nonspecific inflammatory diseases characterized by chronic inflammation and abnormal gastrointestinal epithelial barrier. Patients will experience periodic abdominal pain, vomiting, fever, bloody stools, diarrhea, weight loss, and even increase the risk of colorectal cancer. Although the cause of IBD has not been fully elucidated, current research believes that it is the combined effect of genetic, environmental, psychological and other factors, leading to neuroendocrine dysfunction, intestinal mucosal barrier damage, immune imbalance, and thus causing local intestinal mucosal damage.

[0003] Impaired epithelial barrier function is a typical symptom of IBD. Inflammation can disrupt the integrity of the intestinal barrier, leading to pathogen translocation and infiltration of apical tight junction proteins. As key players in epithelial barrier function in inflammatory bowel disease, tight junction proteins are essential for maintaining epithelial barrier function and controlling paracellular permeability. Therefore, to date, the relationship between the imbalance of tight junction (TJ) proteins and the occurrence of intestinal inflammation is unclear. However, studies have pointed out that an imbalance in tight junction protein expression may precede intestinal inflammation, suggesting that in addition to inhibiting the inflammatory response, treating IBD by restoring the integrity of the epithelial barrier may also be a future trend.

[0004] Currently, the drugs used in clinical treatment of inflammatory bowel disease mainly include: glucocorticoids, immunosuppressants, etc., but these therapeutic drugs are accompanied by certain side effects (such as nephrotoxicity, hemolytic anemia, osteoporosis, insomnia and pancreatitis), cannot be used for a long time and cannot completely control IBD. Summary of the invention

[0005] In order to overcome the deficiencies of the prior art, the object of the present invention is to provide the use of D-cycloserine in the preparation of a medicament for preventing / treating inflammatory bowel disease.

[0006] The purpose of the present invention is achieved through the following technical solutions:

[0007] Use of D-cycloserine in the preparation of a drug for preventing / treating inflammatory bowel disease, wherein the structural formula of the D-cycloserine is as follows:

[0008]

[0009] The present invention has found that D-cycloserine can prevent and / or treat inflammatory bowel disease by reducing the levels of inflammatory factors IL-1β and / or IL-18 and / or IL-6 in peripheral blood and colon tissue, by reducing and upregulating colon tight junction proteins and reducing intestinal barrier permeability; and D-cycloserine has no obvious liver and kidney toxicity.

[0010] Therefore, the present invention also provides the use of D-cycloserine in the preparation of a drug for reducing the level of inflammatory factors IL-1β and / or IL-18 and / or IL-6.

[0011] The present invention also provides application of D-cycloserine in preparing a medicine for promoting the expression of colon tight junction protein.

[0012] The present invention also provides application of D-cycloserine in preparing a drug for reducing intestinal barrier permeability.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] The D-cycloserine disclosed in the present invention is obtained by direct chemical synthesis. It is verified by LPS-induced NCM460 cell inflammation model test and DSS-induced mouse IBD model test that at the NCM460 cell level, D-cycloserine can effectively reduce the levels of IL-1β and IL-18; upregulate the expression of tight junction proteins; at the individual level, D-cycloserine can significantly reduce the disease activity index (weight, stool characteristics and blood in stool) of IBD mice; at the tissue level, D-cycloserine can effectively alleviate the damage of colon tissue structure and the reduction of goblet cells without causing damage to the liver and kidneys; at the biochemical level, D-cycloserine can play a role without causing abnormal liver and kidney indicators; at the molecular level, D-cycloserine can reduce the inflammatory factors IL-1β and / or IL-18 in peripheral blood and colon tissue, and can also upregulate tight junction proteins, proving that D-cycloserine may prevent and treat IBD by anti-inflammatory and upregulating tight junction proteins-protecting the intestinal barrier. The experiment of the present invention verifies that D-cycloserine can be applied to the preparation of drugs for preventing and / or treating inflammatory bowel disease, thereby providing a feasible solution for preventing neurodegenerative diseases in clinical medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is the structural formula of D-cycloserine;

[0016] Figure 2 The alleviating effect of D-cycloserine of the present invention on the LPS-induced NCM460 cell inflammation model: (a) cell viability, (b) qPCR and ELISA detection of inflammatory factors, and (c) cell apoptosis detection;

[0017] Figure 3The preventive and therapeutic effects of D-cycloserine on the DSS-induced IBD model in mice: (a) schematic diagram of mouse modeling and drug administration, (b) statistics of mouse mortality, (c) curve of mouse body weight changes, (d) statistics of mouse disease activity index, (e) statistics of spleen and thymus index, (f) statistics of mouse colon length, (g) HE staining of mouse colon tissue sections;

[0018] Figure 4 The protective effect of D-cycloserine on the colon intestinal barrier of the mouse IBD model is detected: (a) PAS staining results of mouse colon, (b) intestinal permeability detection of mice, (c) qPCR detection of mouse colon TJ protein, (d) Western blot detection of mouse colon TJ protein;

[0019] Figure 5 The effects of D-cycloserine on liver and kidney function loss in mice are examined as described in the present invention: (a) normal range of blood biochemical indicators in mice, (b) blood biochemical liver and kidney function tests in mice, and (c) HE staining of mouse liver and kidney. DETAILED DESCRIPTION

[0020] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with specific drawings and embodiments. In the embodiments, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0021] Example 1D-Determination of the alleviating effect of cycloserine on LPS-induced NCM460 cell inflammation model

[0022] 1. Test methods

[0023] NCM460 cells were cultured at a density of 1×10 4 / mL was inoculated into a 96-well plate. After the cells were normally attached and grew to 80%, D-cycloserine was added and treated for 24h, then LPS was added for 8h, and finally the medium containing 10% CCK8 was replaced and incubated at 37℃ in the dark for 1h, and then the cell viability was measured using an ELISA reader at 450nm. The culture medium after LPS treatment for 8h was collected and centrifuged at 3000rpm / min for 15min at 4℃, and the supernatant was collected for inflammatory factor detection by ELISA kit. Relevant cells were collected for total RNA extraction, RNA reverse transcription and qPCR detection. The relevant primers are shown in Table 1. GraphpadPrism8.0 was used for drawing, and the data were expressed as mean ± SEM. One-wayANOVA and Dunnett's post hoc test were used to evaluate the differences between the groups, and P<0.05 was considered significant.

[0024] 2. Results

[0025] like Figure 2 As shown in Figure 2, D-cycloserine did not reduce the cell viability of NCM460 cells, while significantly increasing the cell viability of NCM460 cells under LPS treatment ( Figure 2 a), and significantly inhibited the expression of inflammatory factors IL-1β, IL-18 and TNF-α (Figure b), and reduced cell apoptosis (Figure c).

[0026] The above results showed that D-cycloserine could effectively reverse LPS-induced cellular inflammation and apoptosis.

[0027] Example 2D-Cycloserine can effectively reverse LPS-induced cellular inflammation and apoptosis

[0028] 1. Test methods

[0029] Male mice aged 4-6 weeks were taken for the experiment. After a one-week adaptation period, the mice were randomly divided into 4 groups according to their body weight, with 6 mice in each group. Control group (CON group): gavage 100 μL of PBS daily; Modeling group (DSS group): gavage 100 μL of PBS daily, add 3% DSS to the drinking water on the 8th day and continue to feed for 7 days, and gavage 100 μL of PBS daily during DSS treatment; Prevention group (DC-Prevention, DC-P): mice were gavaged with 200 mg / kg 100 μL of D-cycloserine daily, add 3% DSS to the drinking water on the 8th day and continue to feed for 7 days, and gavage 200 mg / kg 100 μL of D-cycloserine daily during DSS treatment; Treatment group (DC-Therapy, DC-T): gavage 100 μL of PBS daily, add 3% DSS to the drinking water on the 8th day and continue to feed for 7 days, and gavage 200 mg / kg 100 μL of D-cycloserine daily during DSS treatment.

[0030] The formal test period was 14 days, and body weight, stool characteristics, and occult blood were measured daily during DSS treatment. Mouse samples were collected on the 15th day, and blood was collected after the mice were anesthetized with 1.25% tribromoethanol and then killed. The spleen and thymus of the mice were taken and the weight of the spleen and thymus was measured. The colon tissue of the mice was taken, its length was measured, and representative pictures were taken. The colon tissue was then fixed in 4% paraformaldehyde for HE staining observation or placed in liquid nitrogen for quick freezing.

[0031] Graphpad Prism 8.0 was used to draw graphs. The data were expressed as mean ± SEM. One-way ANOVA and Dunnett's post hoc test were used to evaluate the differences among the groups. P < 0.05 was considered to be significant.

[0032] 2. Results

[0033] like Figure 5 As shown, compared with the DSS group, the DC-T group and the DC-P group both reduced the mortality rate of mice ( Figure 3 b), significantly alleviated the relative weight loss ( Figure 3 c) Reduced the disease activity index ( Figure 3 d) and spleen index ( Figure 3 e). In terms of colon, the colon of mice in the DSS group was significantly shorter than that in the CON group, while the colon lengths of mice in the DC-P and DC-T groups were significantly longer than those in the DSS group and comparable to those in the CON group ( Figure 3 f). HE staining results showed that the colon mucosal structure was unclear in the DSS group, with inflammatory cell infiltration in the lamina propria and submucosal layer, accompanied by submucosal edema. Compared with the DSS group, the structural damage, inflammatory cell infiltration, and submucosal edema in the DC-T and DC-P groups were significantly improved ( Figure 3 g).

[0034] The above results showed that both preventive and therapeutic administration of D-cycloserine could significantly alleviate the mortality, weight loss, increased disease activity index, increased spleen index, shortened colon length and colon structural damage of mice caused by DSS-induced inflammatory bowel disease.

[0035] Example 3D-cycloserine can increase the expression of tight junction proteins and protect the integrity of the intestinal barrier

[0036] 1. Test methods

[0037] The colon tissue of mice was collected, and total RNA and total protein were extracted for qPCR and western blot detection. Serum was collected for ELISA detection of intestinal permeability indicators. The relevant primers are shown in Table 1. Graphpad Prism 8.0 was used for plotting, and the data were expressed as mean ± SEM. One-way ANOVA and Dunnett's post hoc test were used to evaluate the differences between the groups, and P < 0.05 was considered significant.

[0038] 2. Results

[0039] like Figure 4 As shown, compared with the DSS group, the number of goblet cells in the DC-T and DC-P groups was significantly restored ( Figure 4 a), while the serum D-LA, DAO and LPS levels in the DC-T and DC-P groups decreased significantly ( Figure 4 b). Both the DC-T group and the DC-P group significantly upregulated the mRNA of tight junction proteins ZO-1, Occludin and Claudin 1 in colon tissue ( Figure 4 c) and protein ( Figure 4d) Expression.

[0040] The above results show that both preventive and therapeutic administration of D-cycloserine can restore the colon structure and goblet cell number of mice, and can significantly upregulate the expression of tight junction proteins, thereby protecting the integrity of the intestinal barrier.

[0041] Example 4D-cycloserine has no hepatotoxicity to mice

[0042] 1. Test methods

[0043] Mouse serum was collected and analyzed by biochemical analyzer for liver function (ALT, ALB, AST, DBIL, TBIL, ALP and TBA) and kidney function (UA, CREA, UREA) biochemical indicators. Mouse liver and kidney were collected and fixed in 4% paraformaldehyde, and HE staining was used for tissue observation after fixation.

[0044] 2. Results

[0045] like Figure 5 As shown, the blood biochemical test results of each group were within the normal range of mouse blood biochemical indicators ( Figure 5 ab), the same HE-stained sections show no obvious tissue damage ( Figure 5 c).

[0046] The above results showed that both preventive and therapeutic administration of D-cycloserine had no obvious liver and kidney toxicity to mice.

[0047] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. Use of D-cycloserine in the preparation of a drug for preventing / treating inflammatory bowel disease, It is characterized in that The structural formula of the D-cycloserine is as follows:

2. Use of D-cycloserine in the preparation of a drug for reducing the level of inflammatory factors IL-1β and / or IL-18 and / or IL-6, It is characterized in that The structural formula of the D-cycloserine is as follows:

3. Application of D-cycloserine in the preparation of drugs for promoting the expression of colon tight junction proteins, It is characterized in that The structural formula of the D-cycloserine is as follows:

4. Application of D-cycloserine in the preparation of drugs for reducing intestinal barrier permeability, It is characterized in that The structural formula of the D-cycloserine is as follows: